PDE5 Inhibitor Treatment for Insomnia and ED

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for treating insomnia are plagued by side effects, addiction risks, and lack of specificity, with existing medications often having unpredictable efficacy and posing significant health warnings, particularly for older adults.

Innovation Solution

Administering a phosphodiesterase 5 (PDE5) inhibitor, such as avanafil, sildenafil, or tadalafil, to promote post-orgasmic sedation/somnolence/sleep (POS) as a novel approach to treating insomnia, targeting various types of insomnia without manipulating the central nervous system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current state of the art medications are used to treat insomnia, then sleep onset and maintenance can be improved, but side effects and addiction risks increase

Engineering Contradiction:

Improvesleep treatment efficacyVSAvoidside effects and addiction risks

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter from CNS-acting sedative-hypnotics to PDE5 inhibitors, which act through a different biochemical pathway (cGMP-mediated smooth muscle relaxation) to produce sleep-promoting effects without the typical side effects of traditional insomnia medications

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces an intermediary mechanism (PDE5 inhibition leading to increased cGMP) that mediates the sleep-promoting effect without directly acting on CNS receptors, thereby avoiding the harmful effects associated with traditional hypnotic medications

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If sedative hypnotics are prescribed to older adults, then insomnia symptoms can be treated, but health risks and mortality increase

Engineering Contradiction:

Improveinsomnia treatmentVSAvoidmortality and health risks

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the drug class parameter from sedative-hypnotics to PDE5 inhibitors, which have a different safety profile and do not carry the same mortality risks in older adults, while still achieving the therapeutic goal of improving sleep

Inventive Principle:

Principle #35Parameter changes

3Duration of action of stationary object

If benzodiazepines and sedative hypnotics are used, then sleep maintenance can be improved, but confusion and cognitive impairment occur

Engineering Contradiction:

Improvesleep maintenanceVSAvoidconfusion and cognitive impairment

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical/CNS receptor-based mechanism of sedative-hypnotics with a biochemical mechanism (PDE5 inhibition and cGMP pathway) that achieves sleep promotion without the cognitive side effects of traditional medications

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

4Speed

If traditional insomnia medications are administered, then sleep onset can be improved, but drug interactions and abuse potential increase

Engineering Contradiction:

Improvesleep onsetVSAvoiddrug interactions and abuse potential

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter from CNS depression to PDE5 inhibition, which has minimal drug interactions and no abuse potential, while maintaining effective sleep-promoting activity

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS10300068B2Method of treating insomnia

Publication Date: 2019.05.28 ROSENBERG LEON I

AI summary

Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of phosphodiesterase 5 (PDE5) inhibitor to a male individual suffering from insomnia. In addition, due to the PDE5 inhibitor positive effects on addressing erectile dysfunction (ED) in males, the present methods are directed to treating insomnia in patients that also suffer from ED by administering a pharmaceutically effective amount of a PDE5 inhibitor.